Ontology highlight
ABSTRACT:
SUBMITTER: Huen A
PROVIDER: S-EPMC7463651 | biostudies-literature | 2020 Aug
REPOSITORIES: biostudies-literature
Huen Auris A Haverkos Bradley M BM Zain Jasmine J Radhakrishnan Ramchandren R Lechowicz Mary Jo MJ Devata Sumana S Korman Neil J NJ Pinter-Brown Lauren L Oki Yasuhiro Y Barde Prajak J PJ Nair Ajit A Routhu Kasi Viswanath KV Viswanadha Srikant S Vakkalanka Swaroop S Iyer Swaminathan P SP
Cancers 20200815 8
Tenalisib (RP6530), a dual phosphoinositide 3-kinase δ/γ inhibitor was evaluated in a phase I/Ib study for maximum tolerated dose (MTD), pharmacokinetics, and efficacy in patients with relapsed/refractory peripheral and cutaneous T-Cell Lymphoma (TCL). Histologically confirmed (TCL) patients, with ≥1 prior therapy received Tenalisib orally in a 28-day cycle in doses of 200 to 800 mg twice daily (800 mg in fasting and fed state) in escalation phase (<i>n</i> = 19) and 800 mg twice daily (fasting) ...[more]